175 related articles for article (PubMed ID: 38821648)
21. [Clonal evolution of myelodysplastic syndromes].
Kon A
Rinsho Ketsueki; 2020; 61(4):358-367. PubMed ID: 32378581
[TBL] [Abstract][Full Text] [Related]
22. NPM1 mutations may reveal acute myeloid leukemia in cases otherwise morphologically diagnosed as myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms.
Forghieri F; Paolini A; Morselli M; Bigliardi S; Bonacorsi G; Leonardi G; Coluccio V; Maccaferri M; Fantuzzi V; Faglioni L; Colaci E; Soci F; Nasillo V; Messerotti A; Arletti L; Pioli V; Zucchini P; Quadrelli C; Corradini G; Giacobbi F; Vallerini D; Riva G; Barozzi P; Lagreca I; Marasca R; Narni F; Mecucci C; Ottaviani E; Martinelli G; Falini B; Luppi M; Potenza L
Leuk Lymphoma; 2015; 56(11):3222-6. PubMed ID: 25813079
[No Abstract] [Full Text] [Related]
23. Genetic Testing in the Diagnosis and Biology of Myeloid Neoplasms (Excluding Acute Leukemias).
Hasserjian RP; Kelley TW; Weinberg OK; Morgan EA; Fend F
Am J Clin Pathol; 2019 Aug; 152(3):302-321. PubMed ID: 31263893
[TBL] [Abstract][Full Text] [Related]
24. [A revised 4 edition WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues, 2017: myeloid neoplasms].
Kovrigina AM
Arkh Patol; 2018; 80(6):43-49. PubMed ID: 30585592
[TBL] [Abstract][Full Text] [Related]
25. Epigenetic regulation by ASXL1 in myeloid malignancies.
Yang FC; Agosto-Peña J
Int J Hematol; 2023 Jun; 117(6):791-806. PubMed ID: 37062051
[TBL] [Abstract][Full Text] [Related]
26. Mutations in epigenetic regulators in myelodysplastic syndromes.
Nikoloski G; van der Reijden BA; Jansen JH
Int J Hematol; 2012 Jan; 95(1):8-16. PubMed ID: 22234528
[TBL] [Abstract][Full Text] [Related]
27. Diagnostic Challenge and Clinical Dilemma: The Long Reach of Clonal Hematopoiesis.
Osman A; Patel JL
Clin Chem; 2021 Aug; 67(8):1062-1070. PubMed ID: 34263288
[TBL] [Abstract][Full Text] [Related]
28. Clonal evolution and hierarchy in myeloid malignancies.
Takahashi K; Tanaka T
Trends Cancer; 2023 Sep; 9(9):707-715. PubMed ID: 37302922
[TBL] [Abstract][Full Text] [Related]
29. Diagnosis and prognosis are supported by integrated assessment of next-generation sequencing in chronic myeloid malignancies. A real-life study.
Vantyghem S; Peterlin P; Thépot S; Ménard A; Dubruille V; Debord C; Guillaume T; Garnier A; Le Bourgeois A; Wuilleme S; Godon C; Theisen O; Eveillard M; Delaunay J; Maisonneuve H; Morineau N; Villemagne B; Vigouroux S; Subiger F; Lestang E; Loirat M; Parcelier A; Godmer P; Mercier M; Trebouet A; Luque Paz D; Le Calloch R; Le Clech L; Bossard C; Moreau A; Ugo V; Hunault M; Moreau P; Le Gouill S; Chevallier P; Béné MC; Le Bris Y
Haematologica; 2021 Mar; 106(3):701-707. PubMed ID: 32241844
[TBL] [Abstract][Full Text] [Related]
30. Recurrent genetic defects on chromosome 5q in myeloid neoplasms.
Hosono N; Makishima H; Mahfouz R; Przychodzen B; Yoshida K; Jerez A; LaFramboise T; Polprasert C; Clemente MJ; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Sanada M; Cui E; Verma AK; McDevitt MA; List AF; Saunthararajah Y; Sekeres MA; Boultwood J; Ogawa S; Maciejewski JP
Oncotarget; 2017 Jan; 8(4):6483-6495. PubMed ID: 28031539
[TBL] [Abstract][Full Text] [Related]
31. ASXL1 mutation in clonal hematopoiesis.
Fujino T; Kitamura T
Exp Hematol; 2020 Mar; 83():74-84. PubMed ID: 31945396
[TBL] [Abstract][Full Text] [Related]
32. Recent advances in the application of induced pluripotent stem cell technology to the study of myeloid malignancies.
Tatwavedi D; Pellagatti A; Boultwood J
Adv Biol Regul; 2024 Jan; 91():100993. PubMed ID: 37827894
[TBL] [Abstract][Full Text] [Related]
33. Single-cell mutation analysis of clonal evolution in myeloid malignancies.
Miles LA; Bowman RL; Merlinsky TR; Csete IS; Ooi AT; Durruthy-Durruthy R; Bowman M; Famulare C; Patel MA; Mendez P; Ainali C; Demaree B; Delley CL; Abate AR; Manivannan M; Sahu S; Goldberg AD; Bolton KL; Zehir A; Rampal R; Carroll MP; Meyer SE; Viny AD; Levine RL
Nature; 2020 Nov; 587(7834):477-482. PubMed ID: 33116311
[TBL] [Abstract][Full Text] [Related]
34. [Pathophysiology of hematological malignancies associated with ASXL1 mutations].
Fujino T
Rinsho Ketsueki; 2022; 63(6):561-572. PubMed ID: 35831189
[TBL] [Abstract][Full Text] [Related]
35. The New Clinicopathologic and Molecular Findings in Myeloid Neoplasms With inv(3)(q21q26)/t(3;3)(q21;q26.2).
Wang HY; Rashidi HH
Arch Pathol Lab Med; 2016 Dec; 140(12):1404-1410. PubMed ID: 27628325
[TBL] [Abstract][Full Text] [Related]
36. Mutation in TET2 in myeloid cancers.
Delhommeau F; Dupont S; Della Valle V; James C; Trannoy S; Massé A; Kosmider O; Le Couedic JP; Robert F; Alberdi A; Lécluse Y; Plo I; Dreyfus FJ; Marzac C; Casadevall N; Lacombe C; Romana SP; Dessen P; Soulier J; Viguié F; Fontenay M; Vainchenker W; Bernard OA
N Engl J Med; 2009 May; 360(22):2289-301. PubMed ID: 19474426
[TBL] [Abstract][Full Text] [Related]
37. The use of genetic tests to diagnose and manage patients with myeloproliferative and myeloproliferative/myelodysplastic neoplasms, and related disorders.
Cross NCP; Godfrey AL; Cargo C; Garg M; Mead AJ;
Br J Haematol; 2021 Nov; 195(3):338-351. PubMed ID: 34409596
[No Abstract] [Full Text] [Related]
38. Architectural and functional heterogeneity of hematopoietic stem/progenitor cells in non-del(5q) myelodysplastic syndromes.
Chesnais V; Arcangeli ML; Delette C; Rousseau A; Guermouche H; Lefevre C; Bondu S; Diop M; Cheok M; Chapuis N; Legros L; Raynaud S; Willems L; Bouscary D; Lauret E; Bernard OA; Kosmider O; Pflumio F; Fontenay M
Blood; 2017 Jan; 129(4):484-496. PubMed ID: 27856460
[TBL] [Abstract][Full Text] [Related]
39. Relapse and cytogenetic evolution in myeloid neoplasms.
Ertz-Archambault N; Kelemen K
Panminerva Med; 2017 Dec; 59(4):308-319. PubMed ID: 29144072
[TBL] [Abstract][Full Text] [Related]
40. Myelomastocytic overlap syndromes: biology, criteria, and relationship to mastocytosis.
Valent P; Sperr WR; Samorapoompichit P; Geissler K; Lechner K; Horny HP; Bennett JM
Leuk Res; 2001 Jul; 25(7):595-602. PubMed ID: 11377685
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]